ALARION EV Study for Ventricular Arrhythmias

This study is testing a new device called the Parasternal Extravascular ICD System, which includes the Atala™ lead and EV-ICD Pulse Generator. This system is designed to treat serious heart rhythm problems like ventricular arrhythmia, ventricular fibrillation, and ventricular tachycardia. The study aims to see how safe and effective this system is over 6 months. You might be able to join if you are at least 18 years old and your doctor has recommended an ICD (implantable cardioverter-defibrillator) for you. The study is currently enrolling up to 280 participants worldwide.

Study design
This is a single-arm study, meaning all participants receive the new device. Up to 280 people will be enrolled across many sites.
What's involved
You will receive the Atala™ lead and EV-ICD Pulse Generator. You will have follow-up visits every 6 months after the initial 6-month period.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed every 6 months after the initial 6-month period until the study closes, which is expected to be at least 2.5 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07324031

Parasternal Extravascular ICD System Pivotal Clinical Investigation (ALARION EV) Study

Recruiting
NAAges 18+InterventionalTreatment
AtaCor Medical, Inc.
~280 participants
Updated 2026-09-03 on ClinicalTrials.gov
What's tested:Atala™ lead and EV-ICD Pulse Generator

At a glance

Recruiting sites
11 of 35 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Freedom from MADEs
Measured over Through 6 months post-implant
+1 more outcome measured
Ventricular Arrythmia
Ventricular Fibrillation
Ventricular Tachycardia

NCT07324031

Where you'd take part

This study runs at 35 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • AdventHealth

    Orlando, Floridano site contact published

    Not yet recruiting

  • Advocate/Atrium Health - Sanger Heart and Vascular

    Charlotte, North Carolinano site contact published

    Recruiting

  • Advocate/Atrium Health - Wake Forest Baptist

    Winston-Salem, North Carolinano site contact published

    Recruiting

  • Amsterdam University Medical Center

    Amsterdam, AZ, Netherlandsno site contact published

    Recruiting

  • Baptist Health

    Lexington, Kentuckyno site contact published

    Recruiting

  • Cedars-Sinai Medical Center

    Santa Monica, Californiano site contact published

    Not yet recruiting

  • Cooper Health

    Voorhees Township, New Jerseyno site contact published

    Not yet recruiting

  • East Carolina Heart Institute at ECU

    Greenville, North Carolinano site contact published

    Not yet recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Exclusion

Severe aortic stenosis
Current Intracardiac LA or LV thrombus
Severe proximal three-vessel or left main coronary artery disease without revascularization
Hemodynamic instability
Unstable angina
Recent stroke or transient ischemic attack (within the last 3 months)
Known inadequate external defibrillation
LVEF \< 20% (most recent assessment; must be within 180 days of consent)
LVEDD \>70 mm (most recent assessment; must be within 180 days of consent)
  • Freedom from MADEsThrough 6 months post-implant

    Freedom from Major Adverse Device Effects (MADEs)

  • Successful IVA TestAt the time of procedure and up to 60 days post-implant

    Successful induced ventricular arrhythmia (IVA) test in the final system configuration